Results 171 to 177 of about 28,682 (177)

Human medicines European public assessment report (EPAR): Imatinib Teva, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 07/01/

Case Medical Research, 2018

semanticscholar   +1 more source

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Nature Medicine, 1996
B. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. Segal, S. Fanning, J. Zimmermann, N. Lydon   +7 more
semanticscholar   +1 more source

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

Blood, 2000
F. Mahon, M. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, J. Goldman, J. Melo   +6 more
semanticscholar   +1 more source

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

Blood, 2000
J. T. Thiesing, Sayuri Ohno-Jones, K. Kolibaba, B. Druker   +3 more
semanticscholar   +1 more source

Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Phase Chronic Myelogenous Leukemia (CML-CP).

, 2006
E. Jabbour, J. Cortes, F. Giles, S. O'brien, L. Letvak, H. Kantarjian   +5 more
semanticscholar   +1 more source

Nasopharyngeal Carcinoma in Adult Woman with Chronic Myelogenous Leukemia BCR-ABL Positive A Rare Case of Double Primary Malignancy

Kuswanto, Adrian, Agus Jati Sunggoro, Marwanta, Sri, Sihwidhi Dimas Sudarmadi   +3 more
openaire   +1 more source

Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple Myeloma, Date of authorisation: 09/03/2000, Revision: 31, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source